 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Jul 20, 2021 |
| Title |
Serum miRNA profiling for early PDAC diagnosis and prognosis: a retrospective study |
| Organism |
Homo sapiens |
| Experiment type |
Non-coding RNA profiling by array
|
| Summary |
Background: Tumor stage predicts pancreatic cancer (PDAC) prognosis, but prolonged and short survivals have been described in patients with early-stage tumors. Circulating microRNA (miRNA) are an emerging class of suitable biomarkers for PDAC prognosis. Our aim was to identify whether serum miRNA signatures predict survival of early-stage PDAC. Methods: Se-rum RNA from archival 15 stage I-III PDAC patients and 4 controls was used for miRNAs ex-pression profile (Agilent microarrays). PDAC patients with comparable age, gender, diabetes, jaundice and surgery were classified according to survival: less than 14 months (7/15 pts, group A) and more than 22 months (8/15 pts, group B). Bioinformatic data analysis was performed by two-class Significance Analysis of Microarray (SAM) algorithm. Binary logistic regression analyses considering PDAC diagnosis and outcome as dependent variables, and ROC analyses were also performed. Results: 2549 human miRNAs were screened out. At SAM, 76 differen-tially expressed miRNAs were found among controls and PDAC (FDR = 0.4%), the large major-ity (50/76, 66%) of them being downregulated in PDAC with respect to controls. Six miRNAs were independently correlated with early PDAC, and among these, hsa-miR-6821-5p was asso-ciated with the best ROC curve area in distinguishing controls from early PDAC. Among the 71 miRNAs differentially expressed between groups A and B, the most significant were hsa-miR-3135b expressed in group A only, hsa-miR-6126 and hsa-miR-486-5p expressed in group B only. Eight miRNAs were correlated with the presence of lymph-node metastases; among these, hsa-miR-4669 is of potential interest. hsa-miR-4516, increased in PDAC and found as an independent predictor of survival, has among its putative targets a series of gens involved in key pathways of cancer progression and dissemination, such as Wnt and p53 signaling pathways. Conclusions: A series of serum miRNAs was identified as potentially useful for the early diag-nosis of PDAC, and for establishing a prognosis
|
| |
|
| Overall design |
miRNA expression profiles were carried out using the “Agilent SurePrintG3 Human miRNA v.21 (8x60K)” microarrays (Agilent Technologies, Santa Clara, CA, USA)” (Agilent Technologies), that allows the detection of 2.549 known human (miRBase Release 21.0) and 76 viral miRNAs. We analysed expression of circulating miRNAs in 15 PDAC patients as well as 4 reference subjects. An unsupervised hierarchical clustering analysis, by using the list of differentially expressed genes between PDAC patients and controls, enabled the clear separation of controls and PDAC patients with long and short survival, respectively.
|
| Web link |
https://doi.org/10.3390/biomedicines9070845
|
| |
|
| Contributor(s) |
Aita A, Millino C, Sperti C, Pacchioni B, Plebani M, De Pittà C, Basso D |
| Citation(s) |
34356909 |
| |
| Submission date |
Mar 16, 2021 |
| Last update date |
Aug 30, 2021 |
| Contact name |
Cristiano De Pitta |
| E-mail(s) |
[email protected]
|
| Phone |
+390498276210
|
| Organization name |
University of Padova
|
| Department |
Biology
|
| Street address |
Via U. Bassi, 58/B
|
| City |
Padova |
| ZIP/Postal code |
35131 |
| Country |
Italy |
| |
|
| Platforms (1) |
| GPL24741 |
Agilent-070156 Human_miRNA_V21.0_Microarray 046064 (gene name version) |
|
| Samples (19)
|
| GSM5173731 |
PDAC patient with short (< 1 year) survival (pz 301) |
| GSM5173732 |
PDAC patient with short (< 1 year) survival (pz 699) |
| GSM5173733 |
PDAC patient with short (< 1 year) survival (pz 550) |
| GSM5173734 |
PDAC patient with short (< 1 year) survival (pz 607) |
| GSM5173735 |
PDAC patient with short (< 1 year) survival (pz 354) |
| GSM5173736 |
PDAC patient with short (< 1 year) survival (pz 517) |
| GSM5173737 |
PDAC patient with short (< 1 year) survival (pz 584) |
| GSM5173738 |
PDAC patient with long (> 2 years) survival (pz 642) |
| GSM5173739 |
PDAC patient with long (> 2 years) survival (pz 664) |
| GSM5173740 |
PDAC patient with long (> 2 years) survival (pz 708) |
| GSM5173741 |
PDAC patient with long (> 2 years) survival (pz 310) |
| GSM5173742 |
PDAC patient with long (> 2 years) survival (pz 386) |
| GSM5173743 |
PDAC patient with long (> 2 years) survival (pz 585) |
| GSM5173744 |
PDAC patient with long (> 2 years) survival (pz 703) |
| GSM5173745 |
PDAC patient with long (> 2 years) survival (pz 713 |
| GSM5173746 |
Control, non cancer subject (CTRL 287) |
| GSM5173747 |
Control, non cancer subject (CTRL 321) |
| GSM5173748 |
Control, non cancer subject (CTRL 1078) |
| GSM5173749 |
Control, non cancer subject (CTRL 1093) |
|
| Relations |
| BioProject |
PRJNA714878 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE168996_RAW.tar |
200.0 Kb |
(http)(custom) |
TAR (of TXT) |
| Processed data included within Sample table |
|
|
|
|
 |
Less...
More...